title: Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels.
authors.forename: Stefano
authors.initials: S
authors.lastname: Brillanti
authors.forename: Fabio
authors.initials: F
authors.lastname: Levantesi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Nigro
authors.forename: Susanna
authors.initials: S
authors.lastname: Vicari
authors.forename: Enrico
authors.initials: E
authors.lastname: Roda
mesh_terms: D000410:Alanine Transaminase / Q000097:blood*; D000547:Amantadine / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000201:enzymology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000547:Amantadine; D000410:Alanine Transaminase; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a